vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and CEA Industries Inc. (BNC). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $7.1M, roughly 1.5× CEA Industries Inc.). CEA Industries Inc. runs the higher net margin — 3970.6% vs 23.5%, a 3947.2% gap on every dollar of revenue. On growth, CEA Industries Inc. posted the faster year-over-year revenue change (1727.8% vs 522.2%). Over the past eight quarters, CEA Industries Inc.'s revenue compounded faster (18.8% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
CEA Technologies is an Australian government business enterprise that primarily supplies the Royal Australian Navy. The company was established in 1983. Its phase array radars, which are fitted to the Royal Australian Navy's fleet of warships, are regarded by Australians as the best in the world.
ABUS vs BNC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $7.1M |
| Net Profit | $2.5M | $283.6M |
| Gross Margin | — | 29.3% |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | 3970.6% |
| Revenue YoY | 522.2% | 1727.8% |
| Net Profit YoY | 112.7% | 38409.2% |
| EPS (diluted) | $0.01 | $5.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $7.1M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | $10.7M | — | ||
| Q2 24 | — | $1.8M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | $913.6K | ||
| Q2 23 | $4.7M | $1.1M | ||
| Q1 23 | $6.7M | $4.7M |
| Q4 25 | — | $283.6M | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | $2.5M | — | ||
| Q2 24 | — | $-470.3K | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | $-799.0K | ||
| Q2 23 | $-17.1M | $-693.6K | ||
| Q1 23 | $-16.3M | $-431.4K |
| Q4 25 | — | 29.3% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | 10.2% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -11.4% | ||
| Q2 23 | — | 7.4% | ||
| Q1 23 | — | 18.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | -123.2% | ||
| Q2 25 | 13.9% | — | ||
| Q2 24 | — | -27.1% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | -88.3% | ||
| Q2 23 | -395.3% | -66.2% | ||
| Q1 23 | -260.4% | -9.5% |
| Q4 25 | — | 3970.6% | ||
| Q3 25 | — | -127.7% | ||
| Q2 25 | 23.5% | — | ||
| Q2 24 | — | -26.7% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | -87.5% | ||
| Q2 23 | -367.5% | -65.2% | ||
| Q1 23 | -244.3% | -9.2% |
| Q4 25 | — | $5.36 | ||
| Q3 25 | — | $-6.94 | ||
| Q2 25 | $0.01 | — | ||
| Q2 24 | — | $-0.66 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | $-1.19 | ||
| Q2 23 | $-0.10 | $-1.03 | ||
| Q1 23 | $-0.10 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $32.5M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $484.9M |
| Total Assets | $103.3M | $616.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $32.5M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $37.4M | — | ||
| Q2 24 | — | $11.3M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | $13.3M | ||
| Q2 23 | $27.2M | $14.2M | ||
| Q1 23 | $40.6M | $15.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | $0 | — |
| Q4 25 | — | $484.9M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | $83.0M | — | ||
| Q2 24 | — | $10.9M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | $13.2M | ||
| Q2 23 | $134.7M | $14.0M | ||
| Q1 23 | $143.9M | $14.7M |
| Q4 25 | — | $616.5M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | $103.3M | — | ||
| Q2 24 | — | $12.6M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | $14.7M | ||
| Q2 23 | $176.8M | $15.9M | ||
| Q1 23 | $191.2M | $17.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — | ||
| Q1 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $-15.7M | — | ||
| Q2 24 | — | $-273.4K | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | $-854.7K | ||
| Q2 23 | $-19.6M | $-1.8M | ||
| Q1 23 | $-27.3M | $-2.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — | ||
| Q1 23 | $-27.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — | ||
| Q1 23 | -410.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — | ||
| Q1 23 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
